A deeper understanding of osteosarcoma, the most common primary malignant bone tumour affecting children and adolescents, is reshaping strategies for overcoming treatment resistance.

Found in the journal Genes & Diseases.

Central to this breakthrough is Nuclear factor E2-related factor 2 (Nrf2), a transcription factor now recognised as a pivotal player in chemoradiotherapy resistance.

Traditionally acknowledged for its role in antioxidant defence and maintaining cellular homeostasis, Nrf2 emerges in recent insights as a double-edged molecule, offering protection in normal tissues but serving as a survival mechanism in malignant cells.

The overactivation of Nrf2 in cancer cells enables them to withstand oxidative stress, enhance DNA repair, evade apoptosis, and reduce intracellular drug concentration.

These effects are achieved through the activation of the antioxidant response element (ARE), which upregulates enzymes involved in detoxification and drug efflux.

As a result, osteosarcoma cells equipped with elevated Nrf2 expression exhibit multi-drug resistance, undermining the effectiveness of chemotherapeutic agents such as cisplatin, doxorubicin, and methotrexate.

Beyond drug resistance, Nrf2 contributes to radiotherapy resistance by mitigating the damage induced by reactive oxygen species and facilitating DNA double-strand break repair.

Its interaction with pathways such as Keap1-Nrf2-ARE, PI3K/AKT, and autophagy networks highlights its extensive involvement in orchestrating cellular responses that defend tumour survival.

The crosstalk between Nrf2 and regulated cell death mechanisms, including ferroptosis and autophagy, further underscores its centrality in osteosarcoma progression.

Notably, Nrf2 also supports tumour proliferation and metastasis by driving metabolic reprogramming and enabling epithelial-to-mesenchymal transition.

Its elevated expression in osteosarcoma correlates negatively with patient survival, affirming its oncogenic potential.

While therapeutic inhibition of Nrf2 remains challenging due to its protective role in normal tissues, preclinical approaches using agents like ML385 and natural compounds such as oridonin have shown promise in reversing resistance and reducing tumour burden.

This exploration into Nrf2’s multifaceted role marks a significant advancement in the quest to overcome treatment resistance in osteosarcoma.

As research continues to unravel its regulatory mechanisms, Nrf2 is being spotlighted as a potential therapeutic target that could revolutionise future interventions for aggressive paediatric bone cancers.

Source: Compuscript Ltd